成都欧林生物科技股份有限公司第七届董事会 二、独立董事专门会议审议情况 本着勤勉尽责、客观公正的原则，经与会独立董事审议，以投票表决方式通 过以下议案： （一）审议通过了《关于终止以简易程序向特定对象发行 A 股股票事项并 撤回申请文件的议案》 经审阅，我们认为：本次终止以简易程序向特定对象发行股票事项，系公司 根据实际情况作出的审慎决策，不会对公司生产经营和业务发展造成不利影响， 不存在损害公司及全体股东利益的情形。因此，我们一致同意《关于终止以简易 程序向特定对象发行 A 股股票事项并撤回申请文件的议案》。 独立董事专门会议 2025 年第二次会议决议 一、独立董事专门会议召开情况 表决结果：同意 3 票；反对 0 票；弃权 0 票。 成都欧林生物科技股份有限公司（以下简称"公司"）第七届董事会独立董 事专门会议 2025 年第二次会议于 2025 年 8 月 29 日在公司会议室以现场及通讯 方式召开。本次会议由独立董事陈正旭先生主持，应出席独立董事 3 名，实际出 席独立董事 3 名。本次会议的召集和召开程序符合《上市公司独立董事管理办法》 《上海证券交易所科创板股票上市规则》的相关规定，会议决议合法 ...

成都欧林生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日以 现场及通讯方式在公司会议室召开第七届董事会第四次会议（以下简称"本次会 议"）。经全体董事同意，本次会议豁免通知时限要求。本次会议由公司董事长 樊绍文先生召集并主持，应出席董事 9 人，实际出席会议董事 9 人。本次会议的 通知、召开及审议程序符合《中华人民共和国公司法》《上海证券交易所科创板 股票上市规则》等法律法规、规范性文件及《成都欧林生物科技股份有限公司章 程》（以下简称"《公司章程》"）的有关规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议，本次会议通过如下议案： （一）审议通过了《关于终止以简易程序向特定对象发行 A 股股票事项并 撤回申请文件的议案》 证券代码：688319 证券简称：欧林生物 公告编号：2025-041 成都欧林生物科技股份有限公司 第七届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 本次终止以简易程序向特定对象发行股票事项，系公司根据实际 ...

Core Viewpoint - Olin Bio (688319.SH) announced that its subsidiary, XinNuoMing Bio, will transfer a total of 15% equity held by minority shareholders, Yihua Fund and JingChuang Fund, through a public transfer at the Southwest United Property Exchange [1] Group 1: Equity Transfer Details - The company plans to acquire the total 15% equity at a price not exceeding 5% above the listed base price and not exceeding RMB 45 million through competitive bidding [1] - The acquisition includes 8.1081% equity from Yihua Fund and 6.8919% equity from JingChuang Fund [1] Group 2: Strategic Implications - The completion of this equity acquisition will enhance the company's control and management efficiency over its subsidiary [1] - This move is expected to strengthen the overall strategic synergy and resource integration of the company [1]

欧林生物8月31日公告，公司控股子公司新诺明生物少数股权股东一号基金以及菁创基金拟通过西南联 合产权交易所公开转让方式转让其合计持有的新诺明生物15%股权。公司拟以不超过标的股权挂牌底价 上浮5%且不超过人民币4500万元的自筹资金通过竞价方式收购一号基金及菁创基金持有的新诺明生物 合计15.00%股权。其中，拟收购一号基金持有的新诺明生物8.1081%的股权、菁创基金持有的新诺明生 物6.8919%的股权。 ...

格隆汇8月31日丨欧林生物(688319.SH)公布，公司拟以自筹资金收购成都生物城一号股权投资基金合伙 企业(有限合伙)(以下简称"一号基金")、 成都生物城菁创股权投资基金合伙企业(有限合伙)(以下简称"菁 创基金")合计持有的公司控股子公司成都新诺明生物科技有限公司(以下简称"新诺明生物"或"标的公 司")15%的股权。 ...

截至目前，公司生产经营一切正常，"疫苗研发生产基地技术改造项目"仍按计划有序推进。终止本次向 特定对象发行股票事项不会对公司的日常生产经营造成重大不利影响，不存在损害公司及全体股东利益 的情形。 智通财经APP讯，欧林生物(688319.SH)发布公告，自公司首次公告以简易程序向特定对象发行股票事 项以来，公司董事会、管理层与中介机构等一直积极推进各项工作。鉴于当前市场情况，结合公司实际 情况及发展规划等诸多因素，经公司审慎分析，决定终止本次以简易程序向特定对象发行股票的相关事 项。 ...

Core Viewpoint - Olin Bio (688319.SH) announced that its subsidiary, XinNuoMing Bio, will transfer a total of 15% equity held by minority shareholders, Fund No.1 and JingChuang Fund, through a public transfer at the Southwest United Property Exchange [1] Group 1 - The company plans to acquire the 15% equity stake for no more than 45 million RMB, with a potential increase of up to 5% over the listed base price [1] - The acquisition includes 8.1081% equity from Fund No.1 and 6.8919% equity from JingChuang Fund [1] - This acquisition is expected to enhance the company's control and management efficiency over its subsidiary, contributing to overall strategic synergy and resource integration [1]

Core Viewpoint - The company has decided to terminate the issuance of shares to specific targets through a simplified procedure due to current market conditions and its own development plans [1] Group 1 - The company's board, management, and intermediaries have been actively working on the share issuance since the initial announcement [1] - The decision to terminate the share issuance will not adversely affect the company's normal production and operations [1] - The "Vaccine R&D Production Base Technical Transformation Project" is progressing as planned [1]

据证券之星公开数据整理，近期欧林生物（688319）发布2025年中报。根据财报显示，欧林生物营收净 利润同比双双增长。截至本报告期末，公司营业总收入3.06亿元，同比上升35.17%，归母净利润 1319.69万元，同比上升147.22%。按单季度数据看，第二季度营业总收入2.18亿元，同比上升40.44%， 第二季度归母净利润2027.08万元，同比上升1139.49%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率93.17%，同比减1.47%，净利率4.33%，同比增 131.86%，销售费用、管理费用、财务费用总计1.85亿元，三费占营收比60.59%，同比减11.73%，每股 净资产2.28元，同比增5.07%，每股经营性现金流-0.05元，同比增65.85%，每股收益0.03元，同比增 147.31% 证券之星价投圈财报分析工具显示： 商业模式：公司业绩主要依靠研发及营销驱动。需要仔细研究这类驱动力背后的实际情况。 财报体检工具显示： 建议关注公司现金流状况（货币资金/流动负债仅为42.39%、近3年经营性现金流均值/流动负债仅为 0.68%） 建议关注公司债务状况（有息资产负债率已达21. ...

Market Overview - The biopharmaceutical sector increased by 0.85% on August 29, with Kangchen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Gainers in Biopharmaceutical Sector - Kangchen Pharmaceutical (603590) closed at 56.17, up 10.01% with a trading volume of 67,100 shares and a transaction value of 366 million [1] - Rongchang Biopharmaceutical (688331) closed at 90.88, up 8.35% with a trading volume of 166,100 shares [1] - Sanofi Biopharmaceutical (688336) closed at 52.60, up 8.01% with a trading volume of 89,900 shares [1] - Baipusais (301080) closed at 58.61, up 7.34% with a trading volume of 42,800 shares [1] - Wanzhe Co. (000534) closed at 17.70, up 6.31% with a trading volume of 382,900 shares [1] Top Losers in Biopharmaceutical Sector - Tibet Pharmaceutical (600211) closed at 47.16, down 3.42% with a trading volume of 193,800 shares and a transaction value of 912 million [2] - Wendi Pharmaceutical (688488) closed at 17.36, down 2.36% with a trading volume of 126,200 shares [2] - Chengda Biopharmaceutical (688739) closed at 27.90, down 2.35% with a trading volume of 50,700 shares [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 506 million from institutional investors, while retail investors saw a net inflow of 402 million [2] - The top stocks by net inflow from institutional investors included Rongchang Biopharmaceutical with a net inflow of 127 million [3] - Kangchen Pharmaceutical had a net inflow of 68 million from institutional investors, but also saw outflows from retail investors [3]